Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9116) 9116
Book Review (1572) 1572
Publication (1197) 1197
Newsletter (315) 315
Newspaper Article (98) 98
Book Chapter (59) 59
Conference Proceeding (22) 22
Dissertation (12) 12
Magazine Article (6) 6
Trade Publication Article (4) 4
Book / eBook (2) 2
Data Set (2) 2
Presentation (2) 2
Transcript (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8051) 8051
humans (5850) 5850
animals (4920) 4920
angiogenesis (4172) 4172
vascular endothelial growth factor (4021) 4021
mice (2733) 2733
vascular endothelial growth factor receptor-2 - metabolism (2718) 2718
female (2541) 2541
male (2444) 2444
endothelial growth-factor (2207) 2207
oncology (1879) 1879
expression (1792) 1792
vascular endothelial growth factor a - metabolism (1789) 1789
cancer (1700) 1700
vegf (1632) 1632
research (1397) 1397
cell biology (1383) 1383
vascular endothelial growth factor receptor-2 - genetics (1239) 1239
endothelium (1217) 1217
cells, cultured (1183) 1183
signal transduction (1136) 1136
cells (1069) 1069
middle aged (1055) 1055
neovascularization (1046) 1046
analysis (983) 983
adult (959) 959
rats (950) 950
proteins (901) 901
vascular endothelial growth factor a - genetics (881) 881
physiological aspects (864) 864
endothelial cells - metabolism (861) 861
aged (850) 850
tumors (833) 833
gene expression (825) 825
biochemistry & molecular biology (822) 822
endothelial cells (813) 813
in-vivo (809) 809
care and treatment (804) 804
health aspects (800) 800
apoptosis (787) 787
rodents (787) 787
cell line, tumor (782) 782
article (781) 781
immunohistochemistry (773) 773
research article (752) 752
peripheral vascular disease (749) 749
medicine (747) 747
cell proliferation (743) 743
mice, inbred c57bl (738) 738
vascular endothelial growth factor receptor-2 - antagonists & inhibitors (713) 713
metastasis (693) 693
in-vitro (688) 688
phosphorylation (687) 687
disease models, animal (662) 662
kinases (651) 651
hematology (645) 645
inflammation (643) 643
physiology (643) 643
tumor angiogenesis (632) 632
angiogenesis inhibitors - pharmacology (625) 625
medicine, research & experimental (613) 613
multidisciplinary sciences (606) 606
abridged index medicus (603) 603
hypoxia (589) 589
activation (587) 587
cell proliferation - drug effects (586) 586
bevacizumab (580) 580
neovascularization, pathologic - metabolism (564) 564
medicine & public health (561) 561
growth-factor (555) 555
biology (554) 554
pharmacology & pharmacy (543) 543
cardiovascular system (542) 542
cardiac & cardiovascular systems (540) 540
endothelial cells - cytology (533) 533
genetic aspects (529) 529
growth (526) 526
signal transduction - drug effects (526) 526
neovascularization, physiologic (507) 507
angiogenesis inhibitors - therapeutic use (502) 502
neovascularization, pathologic - drug therapy (502) 502
science (501) 501
inhibition (497) 497
endothelium, vascular - metabolism (496) 496
vascular endothelial growth factor receptor-1 - metabolism (492) 492
development and progression (490) 490
therapy (488) 488
endothelial cells - drug effects (484) 484
endothelium, vascular - cytology (476) 476
neovascularization, physiologic - drug effects (469) 469
receptors (469) 469
stem cells (460) 460
endothelial-cells (458) 458
studies (456) 456
chemotherapy (451) 451
time factors (442) 442
neovascularization, pathologic - pathology (438) 438
cell line (432) 432
mice, nude (430) 430
risk factors (425) 425
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9530) 9530
Chinese (43) 43
Japanese (3) 3
Polish (3) 3
Russian (3) 3
French (2) 2
German (2) 2
Spanish (2) 2
Swedish (2) 2
Ukrainian (2) 2
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth
by Ebos, John M. L and Lee, Christina R and Bogdanovic, Elena and Alami, Jennifer and Van Slyke, Paul and Francia, Giulio and Xu, Ping and Mutsaers, Anthony J and Dumont, Daniel J and Kerbel, Robert S
Cancer Research, ISSN 0008-5472, 01/2008, Volume 68, Issue 2, pp. 521 - 529
Vascular endothelial growth factor (VEGF) is a potent proangiogenic protein that activates VEGF receptor (VEGFR) tyrosine kinases expressed by,vascular... 
ONCOLOGY | METASTATIC BREAST-CANCER | IN-VIVO | VEGF RECEPTOR-1 | SERUM | LEUKEMIA | EXPRESSION | RENAL-CELL CARCINOMA | ANGIOGENIC FACTORS | MYELODYSPLASTIC SYNDROMES | ANTITUMOR EFFICACY | Neoplasm Transplantation | Prostatic Neoplasms - metabolism | Adenocarcinoma - pathology | Adenoviridae | Cell Proliferation | Humans | Male | Transplantation, Heterologous | Mammary Neoplasms, Experimental - metabolism | Vascular Endothelial Growth Factor A - genetics | Mammary Neoplasms, Experimental - genetics | Adenocarcinoma - metabolism | Prostatic Neoplasms - genetics | Mammary Neoplasms, Experimental - pathology | Female | Tumor Burden - genetics | Adenocarcinoma - genetics | Tumor Cells, Cultured | Prostatic Neoplasms - pathology | Transduction, Genetic | Mice, Inbred C57BL | Solubility | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Mice, Transgenic | Biomarkers, Tumor - blood | HT29 Cells | Animals | Mice | Mice, Inbred BALB C | Vascular Endothelial Growth Factor A - physiology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
by Chiorean, E. Gabriela and Hurwitz, H.I and Cohen, R.B and Schwartz, J.D and Dalal, R.P and Fox, F.E and Gao, L and Sweeney, C.J
Annals of Oncology, ISSN 0923-7534, 06/2015, Volume 26, Issue 6, pp. 1230 - 1237
Background: Ramucirumab is a fully human immunoglobulin G1 monoclonal antibody receptor antagonist designed to block the ligand-binding site of vascular... 
Phase I study | Ramucirumab | Solid tumors | Vascular endothelial growth factor | VEGFR-2 | TRIAL | METASTASIS | ANGIOGENESIS | ONCOLOGY | ramucirumab | vascular endothelial growth factor | LYMPHANGIOGENESIS | VEGF-C | phase I study | solid tumors | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Vascular Endothelial Growth Factor Receptor-2 - immunology | Angiogenesis Inhibitors - blood | Antibodies, Monoclonal - blood | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - administration & dosage | Neoplasms - blood | Adult | Female | Angiogenesis Inhibitors - adverse effects | Drug Administration Schedule | Vascular Endothelial Growth Factor A - blood | Antibodies, Monoclonal - pharmacokinetics | Neoplasms - enzymology | Vascular Endothelial Growth Factor Receptor-2 - blood | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Disease Progression | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Neoplasms - immunology | Aged | Neoplasms - pathology | Vascular Endothelial Growth Factor Receptor-1 - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular Cancer
by Zhu, Andrew X and Finn, Richard S and Mulcahy, Mary and Gurtler, Jayne and Sun, Weijing and Schwartz, Jonathan D and Dalal, Rita P and Joshi, Adarsh and Hozak, Rebecca R and Xu, Yihuan and Ancukiewicz, Marek and Jain, Rakesh K and Nugent, Francis W and Duda, Dan G and Stuart, Keith
Clinical Cancer Research, ISSN 1078-0432, 12/2013, Volume 19, Issue 23, pp. 6614 - 6623
Purpose: To assess the efficacy and safety of the anti-VEGF receptor-2 (VEGFR-2) antibody ramucirumab as first-line therapy in patients with advanced... 
SURVIVAL | THERAPY | ONCOLOGY | BEVACIZUMAB | IMC-1121B | DOUBLE-BLIND | SORAFENIB | HYPERTENSION | CARCINOMA | DOCETAXEL | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Liver Neoplasms - mortality | Liver Neoplasms - blood | Pregnancy Proteins - blood | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Carcinoma, Hepatocellular - drug therapy | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Hepatocellular - blood | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Biomarkers, Tumor - blood | Disease-Free Survival | Placenta Growth Factor | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text VEGFR2 alteration in Alzheimer's disease
by Cho, Sun-Jung and Park, Moon Ho and Han, Changsu and Yoon, Keejung and Koh, Young Ho
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 17713 - 17713
Alzheimer's disease (AD) is a common disorder of progressive cognitive decline among elderly subjects. Angiogenesis-related factors including vascular... 
NERVOUS-SYSTEM | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR-2 | CELL-PROLIFERATION | MILD COGNITIVE IMPAIRMENT | TUMOR-GROWTH | EXPRESSION | VASCULAR ENDOTHELIAL GROWTH | ANGIOGENIC FACTORS | BRAIN | BETA | Human Umbilical Vein Endothelial Cells | Angiogenesis Inducing Agents | Humans | Vascular Endothelial Growth Factor Receptor-1 - physiology | Male | Vascular Endothelial Growth Factor A - metabolism | Brain - metabolism | Cognitive Dysfunction - genetics | Female | Vascular Endothelial Growth Factor Receptor-2 - physiology | Disease Models, Animal | Vascular Endothelial Growth Factor Receptor-2 - analysis | Cognitive Dysfunction - metabolism | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor A - analysis | Animals | Vascular Endothelial Growth Factor Receptor-1 - analysis | Alzheimer Disease - metabolism | Vascular Endothelial Growth Factors - metabolism | Aged | Mice | Alzheimer Disease - genetics | Vascular Endothelial Growth Factor Receptor-1 - blood | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dissociation between vascular endothelial growth factor receptor-2 and blood vessel density in the caudate nucleus after chronic hydrocephalus
by Deshpande, Abhishek and Dombrowski, Stephen M and Leichliter, Anna and Krajcir, Natalie and Zingales, Nicholas and Inoue, Masahiro and Schenk, Soren and Fukamachi, Kiyotaka and Luciano, Mark G
Journal of Cerebral Blood Flow & Metabolism, ISSN 0271-678X, 11/2009, Volume 29, Issue 11, pp. 1806 - 1815
Chronic hydrocephalus (CH) is characterized by the presence of ventricular enlargement, decreased cerebral blood flow (CBF), and brain tissue oxygen delivery.... 
Angiogenesis | Hypoxia | Cerebrovascular | Ischemia | Canine | hypoxia | angiogenesis | VEGF | cerebrovascular | canine | CEREBROSPINAL-FLUID | NEUROSCIENCES | FLOW | NEUROPROTECTION | ischemia | HIPPOCAMPUS | ENDOCRINOLOGY & METABOLISM | NORMAL-PRESSURE HYDROCEPHALUS | OBSTRUCTIVE HYDROCEPHALUS | HEMATOLOGY | CEREBRAL-ISCHEMIA | BRAIN | Cardiac Output - physiology | Immunohistochemistry | Neurons - pathology | Cerebrovascular Circulation - physiology | Caudate Nucleus - blood supply | Neuroglia - pathology | Cell Count | Caudate Nucleus - pathology | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Hydrocephalus - pathology | Male | Hydrocephalus - metabolism | Intracranial Pressure - physiology | Caudate Nucleus - metabolism | Magnetic Resonance Imaging | Animals | Hydrocephalus - physiopathology | Dogs | Neuroglia - metabolism | Neurons - metabolism | Chronic Disease | Neovascularization, Physiologic | Disease Models, Animal | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer
by Hu, Xichun and Zhang, Jian and Xu, Binghe and Jiang, Zefei and Ragaz, Joseph and Tong, Zhongsheng and Zhang, Qingyuan and Wang, Xiaojia and Feng, Jifeng and Pang, Danmei and Fan, Minhao and Li, Jin and Wang, Biyun and Wang, Zhonghua and Zhang, Qunling and Sun, Si and Liao, Chunmei
International Journal of Cancer, ISSN 0020-7136, 10/2014, Volume 135, Issue 8, pp. 1961 - 1969
Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial... 
VEGFR2 | triple negative | apatinib | metastatic breast cancer | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Lymphatic Metastasis | Triple Negative Breast Neoplasms - mortality | Triple Negative Breast Neoplasms - drug therapy | Disease-Free Survival | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Lung Neoplasms - secondary | Triple Negative Breast Neoplasms - blood | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Lung Neoplasms - blood | Pyridines - pharmacology | Pyridines - therapeutic use | Hypertension | Medical research | Anthracyclines | Anemia | Medicine, Experimental | Breast cancer | Metastasis | Vascular endothelial growth factor | Chemotherapy | Medical treatment | Ovarian cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by Cameron, David, Prof and Brown, Julia, Prof and Dent, Rebecca, MD and Jackisch, Christian, MD and Mackey, John, Prof and Pivot, Xavier, MD and Steger, Guenther G, Prof and Suter, Thomas M, Prof and Toi, Masakazu, Prof and Parmar, Mahesh, DPhil and Laeufle, Rita, MD and Im, Young-Hyuck, MD and Romieu, Gilles, MD and Harvey, Vernon, MD and Lipatov, Oleg, MD and Pienkowski, Tadeusz, MD and Cottu, Paul, MD and Chan, Arlene, Prof and Im, Seock-Ah, Prof and Hall, Peter S, PhD and Bubuteishvili-Pacaud, Lida, MD and Henschel, Volkmar, PhD and Deurloo, Regula J, PhD and Pallaud, Celine, PhD and Bell, Richard, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 933 - 942
Summary Background The addition of bevacizumab to chemotherapy improves progression-free survival in metastatic breast cancer and pathological complete... 
Hematology, Oncology and Palliative Medicine | COLON-CANCER | PLUS DOCETAXEL | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Humans | Middle Aged | Vascular Endothelial Growth Factor A - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Vascular Endothelial Growth Factor Receptor-2 - blood | Receptors, Estrogen - analysis | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Breast Neoplasms - drug therapy | Bevacizumab | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Chemotherapy, Adjuvant | Receptor, ErbB-2 - analysis | Breast cancer | Adjuvant treatment | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer
by Dome, Balazs and Timar, Jozsef and Dobos, Judit and Meszaros, Livia and Raso, Erzsebet and Paku, Sandor and Kenessey, Istvan and Ostoros, Gyula and Magyar, Melinda and Ladanyi, Andrea and Bogos, Krisztina and Tovari, Jozsef
Cancer Research, ISSN 0008-5472, 07/2006, Volume 66, Issue 14, pp. 7341 - 7347
Until recently, it was generally accepted that vascularization of tumors arises exclusively from endothelial sprouting. Whether circulating bone marrow-derived... 
ANTIANGIOGENIC THERAPY | ANGIOGENESIS | ONCOLOGY | GROWTH | MARKERS | NEOVASCULARIZATION | NORMALIZATION | TUMOR VASCULATURE | EXPRESSION | CHEMOTHERAPY | BLOOD | Peptides - blood | Humans | Lung Neoplasms - metabolism | Middle Aged | Cadherins - blood | Male | Stem Cells - metabolism | Cadherins - biosynthesis | Neovascularization, Pathologic - blood | Neovascularization, Pathologic - pathology | Vascular Endothelial Growth Factor Receptor-2 - genetics | Flow Cytometry | Biomarkers, Tumor - metabolism | Female | Vascular Endothelial Growth Factor Receptor-2 - biosynthesis | Cadherins - genetics | Lung Neoplasms - blood supply | Carcinoma, Non-Small-Cell Lung - blood supply | Endothelial Cells - metabolism | RNA, Messenger - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Vascular Endothelial Growth Factor Receptor-2 - blood | Glycoproteins - blood | Reverse Transcriptase Polymerase Chain Reaction | AC133 Antigen | Antigens, CD34 - blood | Biomarkers, Tumor - blood | Antigens, CD - blood | RNA, Messenger - blood | Stem Cells - pathology | Carcinoma, Non-Small-Cell Lung - blood | Lung Neoplasms - blood | Endothelial Cells - pathology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease
by Coulon, Stephanie and Francque, Sven and Colle, Isabelle and Verrijken, An and Blomme, Bram and Heindryckx, Femke and De Munter, Steffi and Prawitt, Janne and Caron, Sandrine and Staels, Bart and Van Vlierberghe, Hans and Van Gaal, Luc and Geerts, Anja
Cytokine, ISSN 1043-4666, 08/2012, Volume 59, Issue 2, pp. 442 - 449
► Serum concentration of inflammatory and angiogenic factors in NAFLD patients. ► Gene expression of inflammatory and angiogenic factors in liver of NAFLD... 
Interleukin 6 | Tumor necrosis factor alpha | Vascular endothelial growth factor receptor | Non-alcoholic fatty liver disease | Vascular endothelial growth factor | BIOCHEMISTRY & MOLECULAR BIOLOGY | FACTOR RECEPTOR-1 | IMMUNOLOGY | FACTOR-ALPHA | CELL BIOLOGY | TUMOR-NECROSIS-FACTOR | HEPATOCELLULAR-CARCINOMA | OBESE-PATIENTS | INSULIN-RESISTANCE | IN-VIVO | GENE-EXPRESSION | TNF-ALPHA | ENDOTHELIAL GROWTH-FACTOR | Inflammation - pathology | Liver - pathology | Fatty Liver - pathology | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Male | Vascular Endothelial Growth Factor A - metabolism | Angiogenesis Inducing Agents - blood | Vascular Endothelial Growth Factor A - genetics | Case-Control Studies | Inflammation - blood | Vascular Endothelial Growth Factor Receptor-2 - genetics | Young Adult | Interleukin-6 - blood | Angiogenesis Inducing Agents - metabolism | Non-alcoholic Fatty Liver Disease | Adult | Female | Vascular Endothelial Growth Factor Receptor-1 - genetics | Fatty Liver - genetics | Fatty Liver - blood | Health | Liver - metabolism | Gene Expression Regulation | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Linear Models | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Biopsy | Inflammation - genetics | Vascular Endothelial Growth Factor Receptor-1 - blood | Care and treatment | Liver diseases | Fatty liver | Endothelial growth factors | Analysis | Genes | Gene expression | Endothelium | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Expression of vascular endothelial growth factor receptor-2 or tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization
by Nowak, Grzegorz and Karrar, Azza and Holmén, Carolina and Nava, Silvia and Uzunel, Mehmet and Hultenby, Kjell and Sumitran-Holgersson, Suchitra
Circulation, ISSN 0009-7322, 12/2004, Volume 110, Issue 24, pp. 3699 - 3707
Background - Receptor tyrosine kinases that include vascular endothelial growth factor ( VEGFR)- 1, VEGFR-2, and Tie-2 regulate cardiovascular development and... 
Endothelium-derived factors | Cells | Revascularization | PROGENITOR CELLS | revascularization | CARDIAC & CARDIOVASCULAR SYSTEMS | ANGIOGENESIS | MARKER | TRANSPLANTATION | STEM | endothelium-derived factors | cells | RESTENOSIS | PERIPHERAL VASCULAR DISEASE | NEOVASCULARIZATION | HEMATOLOGY | Chemotaxis, Leukocyte | Endothelium, Vascular - cytology | Leukocytes, Mononuclear - metabolism | Cell Proliferation | Monocytes - cytology | Humans | Endothelial Cells - transplantation | Monocytes - metabolism | Angioplasty, Balloon - adverse effects | Femoral Artery - cytology | Stem Cell Transplantation | Receptor, TIE-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - biosynthesis | Endothelial Cells - metabolism | Mice, Inbred C57BL | Receptor, TIE-2 - biosynthesis | Biomarkers - analysis | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-1 - biosynthesis | Phenotype | Animals | Tunica Intima - cytology | Endothelial Cells - cytology | Mice, Nude | Leukocytes, Mononuclear - cytology | Mice | In Vitro Techniques | Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis | Vascular Endothelial Growth Factor Receptor-1 - blood | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Polymorphisms of KDR Gene Are Associated With Coronary Heart Disease
by Wang, Yibo, PhD and Zheng, Yi, MD and Zhang, Weili, PhD and Yu, Hui, MS and Lou, Kejia and Zhang, Yu and Qin, Qin, MD and Zhao, Bingrang, MD and Yang, Ying, MD and Hui, Rutai, MD, PhD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2007, Volume 50, Issue 8, pp. 760 - 767
Polymorphisms of KDR Gene Are Associated With Coronary Heart Disease Yibo Wang, Yi Zheng, Weili Zhang, Hui Yu, Kejia Lou, Yu Zhang, Qin Qin, Bingrang Zhao,... 
Cardiovascular | Internal Medicine | ENDOTHELIAL PROGENITOR CELLS | REENDOTHELIALIZATION | CARDIAC & CARDIOVASCULAR SYSTEMS | MOBILIZATION | VEGF | RECEPTOR | RISK | UNSTABLE ANGINA | GROWTH-FACTOR | NEOVASCULARIZATION | BLOOD | Promoter Regions, Genetic | Genetic Predisposition to Disease | Humans | Middle Aged | Vascular Endothelial Growth Factor Receptor-2 - blood | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Genotype | Male | Vascular Endothelial Growth Factor A - metabolism | Genetic Markers | Mutation, Missense | Case-Control Studies | Vascular Endothelial Growth Factor Receptor-2 - genetics | Coronary Disease - genetics | China | Aged, 80 and over | Adult | Female | Transcription, Genetic | Aged | Polymorphism, Single Nucleotide | Polymerase chain reaction | Genetic aspects | Neovascularization | Gene mutations | Vascular endothelial growth factor | Coronary heart disease | Body mass index | Cardiovascular disease | Heart attacks | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
by Suttle, A.B and Ball, H.A and Molimard, M and Hutson, T.E and Carpenter, C and Rajagopalan, D and Lin, Y and Swann, S and Amado, R and Pandite, L
British Journal of Cancer, ISSN 0007-0920, 11/2014, Volume 111, Issue 10, pp. 1909 - 1916
Background: Pazopanib, an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor... 
blood pressure | renal cell carcinoma | pazopanib | progression-free survival | trough concentration | VEGF | PHASE-II | FACTOR RECEPTOR | ANTITUMOR | SU11248 | ORAL PAZOPANIB | ONCOLOGY | IMATINIB | SUNITINIB | TYROSINE KINASE INHIBITOR | ENDOTHELIAL GROWTH-FACTOR | Blood Pressure | Prognosis | Follow-Up Studies | Humans | Tissue Distribution | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Renal Cell - drug therapy | Biomarkers, Tumor - analysis | Carcinoma, Renal Cell - pathology | Vascular Endothelial Growth Factor Receptor-2 - blood | Survival Rate | Angiogenesis Inhibitors - pharmacokinetics | Kidney Neoplasms - mortality | Sulfonamides - pharmacokinetics | Randomized Controlled Trials as Topic | Carcinoma, Renal Cell - mortality | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - pharmacokinetics | Kidney Neoplasms - pathology | Kidney Neoplasms - drug therapy | Neoplasm Staging | Clinical Trials, Phase I as Topic | Clinical Trials, Phase II as Topic | Index Medicus | Clinical Study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia
by Chaiworapongsa, Tinnakorn and Romero, Roberto and Savasan, Zeynep Alpay and Kusanovic, Juan Pedro and Ogge, Giovanna and Soto, Eleazar and Dong, Zhong and Tarca, Adi and Gaurav, Bhatti and Hassan, Sonia S
Journal of Maternal-Fetal and Neonatal Medicine, ISSN 1476-7058, 10/2011, Volume 24, Issue 10, pp. 1187 - 1207
Objective: To determine whether maternal plasma concentrations of placental growth factor (PlGF), soluble endoglin (sEng), soluble vascular endothelial growth... 
soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) | sflt-1 | automated assay | IUGR | soluble endoglin (sEng) | preterm labor | soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) angiogenesis | Placental growth factor (PlGF) | Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) | Automated assay | Soluble endoglin (sEng) | Preterm labor | Soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) angiogenesis | Sflt-1 | PREGNANCY-INDUCED HYPERTENSION | PROTEIN-CREATININE RATIO | soluble vascular endothelial growth factor receptor-2 (sVEGFR-2) | angiogenesis | CIRCULATING ANTIANGIOGENIC FACTORS | OBSTETRICS & GYNECOLOGY | UNEXPLAINED FETAL-DEATH | LOW-DOSE ASPIRIN | FACTOR RECEPTOR-1 CONCENTRATION | ADVERSE PERINATAL OUTCOMES | INNATE-IMMUNE-SYSTEM | ENDOTHELIAL GROWTH-FACTOR | FOR-GESTATIONAL-AGE | Prognosis | Humans | Vascular Endothelial Growth Factor Receptor-2 - blood | Receptors, Cell Surface - blood | Biomarkers - blood | Pregnancy | Young Adult | Endoglin | Pregnancy Proteins - blood | Antigens, CD - blood | Obstetrics and Gynecology Department, Hospital | Pre-Eclampsia - blood | Placenta Growth Factor | Adult | Female | Retrospective Studies | Triage | Vascular Endothelial Growth Factor Receptor-1 - blood | Pre-Eclampsia - diagnosis | Index Medicus | placental growth factor (PlGF) | preeclampsia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Reduced serum vascular endothelial growth factor receptor‐2 (sVEGFR‐2) and sVEGFR‐1 levels in gastric cancer patients
by Kikuchi, Shogo and Obata, Yuki and Yagyu, Kiyoko and Lin, Yingsong and Nakajima, Toshifusa and Kobayashi, Osamu and Kikuichi, Masahiro and Ushijima, Ryo and Kurosawa, Michiko and Ueda, Junko
Cancer Science, ISSN 1347-9032, 04/2011, Volume 102, Issue 4, pp. 866 - 869
The relationship between gastric cancer and serum vascular endothelial growth factor receptor‐1 (sVEGFR‐1) and sVEGFR‐2, which are soluble form receptor... 
CIRCULATING LEVELS | PEPSINOGEN | ANGIOGENESIS | ONCOLOGY | VEGF | TRANSFORMING GROWTH-FACTOR-BETA-1 | FACTOR EXPRESSION | RISK | HELICOBACTER-PYLORI | PROGNOSTIC VALUE | CARCINOMA | Prognosis | Stomach Neoplasms - diagnosis | Humans | Middle Aged | Vascular Endothelial Growth Factor A - blood | Vascular Endothelial Growth Factor Recept